Описание
Both oseltamivir carboxylate and methotrexate rely on renal tubular secretion via OAT transporters; theoretically, competition could reduce elimination of either drug, though clinical evidence of a significant interaction is limited.
Механизм
Oseltamivir carboxylate and methotrexate are both substrates of OAT1 and OAT3 renal transporters; co-administration could theoretically inhibit secretion of both drugs.
Клиническое значение
No clinical cases of significant interaction have been published; probenecid (a well-documented OAT inhibitor) doubles oseltamivir exposure, suggesting the pathway is pharmacologically relevant.
Тактика ведения
Routine monitoring is sufficient; no dose adjustment required in patients with normal renal function.
Медицинский отказ от ответственности
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.